Back to News
Feb 3, 2026 4:00 AM

Vitrolife AB (publ) - Fourth quarter and full year report 2025

GOTHENBURG, Sweden, Feb. 3, 2026 /PRNewswire/ -- 

Fourth quarter 

Sales of SEK 891 (959) million, organic growth in local currencies excluding discontinued business* were 6%, 3% growth in local currencies and 7% decrease in SEK, due to a significant currency impact of -10%.

Sales per region, in local currencies, were -1% in EMEA excluding discontinued business, +9% in Americas and +10% in APAC.

Sales per product group, in local currencies excluding discontinued business, were +10% in Consumables, +6% in Technologies and +1% in Genetics.

Gross margin decreased to 58.0% (61.1). Gross margin excluding restructuring costs was 58.6% (61.1).

Earnings before depreciation and amortisation (EBITDA) amounted to SEK 196 (337) million, resulting in an EBITDA margin of 22.0% (35.1). EBITDA excluding restructuring costs amounted to SEK 251 (337) million, resulting in an EBITDA margin of 28.2% (35.1) impacted by negative currency effect.

Restructuring costs of SEK 55 million whereof SEK 6 million in COGS and SEK 49 million in operating expenses.

An impairment charge of SEK 5,357 million was reported as other operating expenses.

Net income amounted to SEK -5,314 (139) million, resulting in earnings per share of SEK -39.24 (1.02). ...